Study #2025-0422
A randomized, controlled, multicenter, phase 3 clinical study comparing vusolimogene oderparepvec in combination with nivolumab versus treatment of physician's choice in patients with advanced melanoma that has progressed on an anti-PD-1 and an anti-CTLA-4 containing treatment regimen [IGNYTE-3]
MD Anderson Study Status
Enrolling
Treatment Agent
Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy
Description
This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regimen (administered either as a combination regimen or in sequence) or who are not candidates for treatment with an anti-CTLA-4 therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Melanoma
Study phase:
Phase III
Physician name:
Rodabe Amaria
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.